First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Recruiting now · Phase 1
Conditions studied: Hematological Malignancy, Solid Tumor
In brief
This phase 1 study is aimed at establishing the safety basis of OT-A201 in the treatment of hematological malignancies and solid tumors. In the dose of escalation part it is to characterize the overall safety and tolerability profile and determine the recommended dose(s) of OT-A201 as monotherapy, and in various combination regimens. Preliminary information about anti-cancer activity will be further explored in the expansion part of the study.
Key facts
- Study ID
- NCT05828459
- Run by
- Onward Therapeutics
- People needed
- 150
- Starts
- 2023-07-10
- Expected to finish
- 2027-07-01
- Last updated by the study team
- 2025-03-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- ICM - Montpellier — Montpellier, France (enrolling)
- Saint-Eloi Hospital - Montpellier (CHU) — Montpellier, France (enrolling)
- Saint-Joseph Hospital - Paris — Paris, France (enrolling)
- Centre Eugène Marquis — Rennes, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.